Streetbeat News

CMPGY

Compass Group Plc

http://www.compass-group.com/

CEO

Dominic Blakemore

Open

33.52

Mkt cap

56B

Volume

26K

High

33.52

P/E Ratio

33.39

52-wk high

34.99

Low

33.05

Div yield

0.02

52-wk low

25.02

Compass has solidified its position as a leader in the U.S. real estate market, showing significant growth in revenue and closed deals despite a declining industry. In Q3, Compass reported a 12% year-over-year revenue increase to $1.49 billion and a 16% rise in closed deals, outperforming the industry's 2% decline.

Portfolio Pulse from

November 15, 2024 | 8:30 am

Compass Pathways plc, a biotechnology company focused on mental health, will present at the Stifel 2024 Healthcare Conference on November 19, 2024.

Portfolio Pulse from

November 14, 2024 | 1:00 pm

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company, announced its participation in investor events in November 2024. This could increase visibility and investor interest in the company.

Portfolio Pulse from

November 13, 2024 | 1:45 pm

Compass Therapeutics, Inc. (Nasdaq: CMPX) reported its third quarter 2024 financial results and provided a corporate update. The company is focused on developing antibody-based therapeutics for oncology.

Portfolio Pulse from

November 12, 2024 | 1:15 pm

The article compares Compass Group PLC (CMPGY) and Shake Shack (SHAK) to determine which is a better value stock in the Retail - Restaurants sector. It focuses on their attractiveness to value investors.

Portfolio Pulse from

November 11, 2024 | 6:00 pm

Compass, Inc. (COMP) is highlighted as a strong momentum stock, suggesting it could be a top pick for momentum investors.

Portfolio Pulse from

November 05, 2024 | 6:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.